William Blair analyst Myles Minter has reiterated their bullish stance on AXSM stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors that highlight Axsome Therapeutics’ promising future. The company’s recent R&D Day showcased a robust pipeline of commercial-stage and late-stage clinical assets, addressing significant unmet needs in neurology and psychiatry. This diverse portfolio, which includes treatments for conditions such as ADHD, major depressive disorder, and binge eating, demonstrates Axsome’s potential to make a substantial impact in the medical field.
Minter’s confidence is further bolstered by the insights shared by key opinion leaders during the event, who emphasized the clinical data and strategic fit of Axsome’s offerings within the current treatment landscape. The upcoming clinical and regulatory milestones for Axsome also contribute to the positive outlook, suggesting that the company is well-positioned for growth and innovation in the coming years.
In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $190.00 price target.